Genaera's research and development expenses for the three- and six-month
periods ended
Genaera's general and administrative expenses for the three- and six-month
periods ended
The Company's cash, cash equivalents and short-term investment balance was
About Genaera
Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a phase 1 trial in obesity. In addition, Genaera has a value-driven, fully out-licensed partnership with MedImmune, Inc. for a second core program that is presently undergoing phase 2 clinical testing in asthma. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value. For further information, please see our website at http://www.genaera.com.
This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding the preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.
GENAERA CORPORATION CONDENSED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) Three Months Ended Six Months Ended June 30, June 30, 2008 2007 2008 2007 Revenues $ 45 $ 2,403 $ 1,354 $ 2,610 Costs and expenses: Research and development 3,549 3,089 7,387 6,559 General and administrative 1,378 1,639 3,563 3,071 4,927 4,728 10,950 9,630 Loss from operations (4,882) (2,325) (9,596) (7,020) Interest income 104 338 280 705 Loss before income taxes (4,778) (1,987) (9,316) (6,315) Income tax benefit -- -- 281 147 Net loss $(4,778) $(1,987) $(9,035) $(6,168) Net loss per share -- basic and diluted $(0.27) $(0.11) $(0.52) $(0.35) Weighted average shares outstanding -- basic and diluted 17,465 17,449 17,464 17,446 CONDENSED BALANCE SHEETS (Unaudited) (In thousands) June 30, December 31, 2008 2007 Cash, cash equivalents and short-term investments $12,759 $20,900 Prepaid expenses and other current assets 469 356 Fixed assets, net 296 374 Other assets 56 56 Total assets $13,580 $21,686 Current liabilities $1,699 $3,377 Other liabilities 56 70 Stockholders' equity 11,825 18,239 Total liabilities and stockholders' equity $13,580 $21,686
SOURCE Genaera Corporation